Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration

Carcinoid heart disease (CaHD) is a complication for patients with metastatic neuroendocrine tumors and carcinoid syndrome. This article reviews major CaHD guidance papers and provides expert clinical perspectives on how to implement these recommendations into clinical practice, with the goal of increasing screening for CaHD, optimizing multidisciplinary collaboration, and discussing exploratory therapies to prevent the development of CaHD. Carcinoid heart disease (CaHD) is an important complication among patients with metastatic neuroendocrine tumors and carcinoid syndrome (CS). CS patients (25%-65%) eventually develop CaHD; these patients face a significantly increased risk of morbidity and mortality. Guidance papers (eg, clinical practice guidelines, consensus guidelines, and expert statements) have been established by major organizations across the disciplines of cardiology and oncology; however, these recommendations are not routinely implemented. The aim of this article is to encourage the integration of current recommendations from national societies into clinical practice. Early screening upon recognition of CS and prior to the development of CaHD symptoms is paramount, as no existing therapies are approved to reverse the fibrotic damage to the heart once it occurs. Valvular replacement is the only definitive treatment for CaHD once it has developed. When patients are noted to have urinary 5-hydroxyindoleacetic acid (5-HIAA) levels >= 300 mu mol/24 h and/or serum N-terminal pro B-type natriuretic peptide (NT-proBNP) levels >260 pg/mL, echocardiography is recommended. Systemic approaches to control tumor growth and hormonal secretion include somatostatin analogs (SSAs), followed by options including peptide receptor radiotherapy (PRRT), everolimus and liver embolization. Telotristat is the primary choice for control of diarrhea refractory to SSA. Diuretics are the mainstay of heart failure symptom management for patients who develop CaHD. Considerations for future research are discussed, including the ongoing TELEHEART (TELotristat Ethyl in a HEART biomarker study) trial involving telotristat and not yet activated CHARRT (Carcinoid Heart disease And peptide Receptor Radiotargetted Therapy) study involving PRRT with lutetium 177 (Lu-177) dotatate.

Automated summary

This article reviews major CaHD guidance papers and provides expert clinical perspectives on how to implement these recommendations into clinical practice, with the goal of increasing screening for CaHD, optimizing multidisciplinary collaboration, and discussing exploratory therapies to prevent the development of CaHD. Early screening and valvular replacement are emphasized as important in managing CaHD.